Evgen Pharma plc
("Evgen" or the "Company")
Posting of Annual Report and Notice of AGM
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that its Annual Report and Accounts for the year ended 31 March 2021, the Notice of Annual General Meeting ("AGM") and a Form of Proxy will be posted to shareholders later today and will be available to download from the Company website shortly.
The Company will hold its AGM on Tuesday, 13 July 2021 at 2pm at its offices in Alderley Park.
Since laws and the UK Government's guidance regarding the COVID-19 pandemic current on Tuesday 13 July 2021 continue to include the enforcement of social distancing and restrictions on indoor meetings, shareholders will not be permitted to attend the AGM and a closed meeting will be held. Accordingly, the business at the AGM will be curtailed to the formal business section only, with no wider presentations on business performance or question and answer session and any relevant shareholder updates will be made via RNS announcements.
Similarly, proxies other than the Chairman will not be able to attend the Meeting in person or cast the shareholder's vote. Shareholders are therefore strongly encouraged to appoint the Chairman of the AGM as their proxy. Details on how to do this are set out on the Form of Proxy being posted to shareholders today.
Any shareholder wishing to ask questions regarding the business of the AGM is encouraged to submit their questions to the Board by email to evgen@walbrookpr.com at least seven days in advance of the AGM. The Board will consider all questions and, if appropriate, will provide a written response.
Enquiries:
| Evgen Pharma plc www.evgen.com | via Walbrook | |
| Dr Huw Jones, CEO | | |
| Richard Moulson, CFO | | |
| | | |
| finnCap www.finncap.com | +44 (0)20 7220 0500 | |
| Geoff Nash / Teddy Whiley (Corporate Finance) | | |
| Alice Lane (ECM) | | |
| | | |
| Walbrook PR | +44 (0)20 7933 87870 or evgen@walbrookpr.com | |
| Anna Dunphy / Paul McManus | +44 (0)7876 741 001 / +44 (0)7980 541 893 | |
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The has its headquarters at Alderley Park, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
